Circulating tumor DNA to drive treatment in metastatic colorectal cancer
In the evolving molecular treatment landscape of metastatic colorectal cancer (mCRC), the
identification of druggable alterations is pivotal to achieve the best therapeutic opportunity …
identification of druggable alterations is pivotal to achieve the best therapeutic opportunity …
A practical approach to interpreting circulating tumor DNA in the management of gastrointestinal cancers
Z Allan, DS Liu, MM Lee, J Tie, NJ Clemons - Clinical Chemistry, 2024 - academic.oup.com
Background There is accumulating evidence supporting the clinical use of circulating tumor
DNA (ctDNA) in solid tumors, especially in different types of gastrointestinal cancer. As such …
DNA (ctDNA) in solid tumors, especially in different types of gastrointestinal cancer. As such …
Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer
OE Emiloju, M Zhu, H Xie, Z Jin, FA Sinicrope… - … treatment options in …, 2023 - Springer
Opinion statement Standard frontline treatment of metastatic colorectal cancer (CRC) is
cytotoxic chemotherapy plus a biologic agent such as an anti-EGFR monoclonal antibody …
cytotoxic chemotherapy plus a biologic agent such as an anti-EGFR monoclonal antibody …
CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice
R D'Onofrio, F Caputo, F Prampolini… - Tumori …, 2023 - journals.sagepub.com
Aim: To apply extended ctDNA-based RAS genotyping to clinical criteria for improving the
selection of patients eligible for anti-EGFR-based rechallenge in a real-world setting …
selection of patients eligible for anti-EGFR-based rechallenge in a real-world setting …
Ongoing clinical trials and future research scenarios of circulating tumor DNA for the treatment of metastatic colorectal cancer
Liquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive,
timely approach to provide molecular diagnosis and monitor tumor evolution in patients with …
timely approach to provide molecular diagnosis and monitor tumor evolution in patients with …
[HTML][HTML] Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial
Background Retreatment with anti-EGFR monoclonal antibodies is a promising strategy in
patients with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) who achieved …
patients with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) who achieved …
China special issue on gastrointestinal tumors‐Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild‐type metastatic …
M Quan, J Chen, Z Chen, Y Hai, Y Zhou… - … Journal of Cancer, 2023 - Wiley Online Library
Patients with metastatic colorectal cancer (mCRC) have poor long‐term survival.
Rechallenge with anti‐epidermal growth factor receptor (anti‐EGFR) based therapy has …
Rechallenge with anti‐epidermal growth factor receptor (anti‐EGFR) based therapy has …